P ain is one of the hallmark symptoms in rheumatoid arthritis (RA), and more than 60% of patients with RA report severe pain. 1 This may be attributable in early stages of the disease to the active inflammation and in later stages to the secondary osteoarthritis (OA). The aim of the treatment besides pain relief is to suppress the disease process to prevent and limit the onset of erosions and the development of deformities and disabilities. 2 A sufficient pain therapy is also extremely important to prevent the pain from becoming chronic. Persistent painful stimulation can induce neuroplastic changes in the central nervous system, which are discussed as one of the pathomechanisms of chronic pain. 3 Hence, a sufficient pain therapy is essential to prevent pain-induced immobilization and pain chronification to improve the patient's overall function and quality of life.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are often the first treatment given to patients with RA because of their anti-inflammatory and pain-relieving properties. 4 Because of their side effects (particularly gastrointestinal toxicity and kidney damage), they can only be used to a limited extent in long-term therapy. [5] [6] [7] The level of analgesia that can be achieved with NSAIDs, however, is not satisfactory in all patients with RA, particularly in late stages of the disease when secondary OA predominates. In these cases, stronger analgesics are often required.
A number of investigators have evaluated the efficacy of opioid administration in the treatment of RA and OA [8] [9] [10] ; however, pain relief was not necessarily accompanied by functional improvement. 10 Transdermal fentanyl 11 has been used successfully in the treatment of other chronic pain syndromes such as back pain. 12, 13 It is approved for the treatment of chronic pain when weaker analgesics have failed. The current prospective, open-label study was conducted to investigate the effectiveness and tolerability of transdermal fentanyl in a treatment regimen in patients with RA under daily routine conditions.
MATERIALS AND METHODS

Patients
Patients were recruited from 55 private practices throughout Germany. Physicians were either rheumatologists with experience in the treatment of pain or pain specialists. Male and female patients diagnosed with RA as defined by the criteria of the American College of Rheumatology 14 were eligible for the study if (1) the decision had been made to add transdermal fentanyl to the treatment regimen, (2) they had unsatisfactory treatment with NSAIDs leading to a level of pain intensity of 6 or more on a 10-point numerical rating scale (NRS), and (3) they had not been treated previously with transdermal fentanyl. The treating physician made the decision for the addition of transdermal fentanyl. Written informed consent was obtained from all patients before enrolment in the study.
Treatment
Transdermal fentanyl is a patch that releases the active ingredient fentanyl, a potent opioid, continuously over a period of 72 hours. The patch, therefore, needs to be changed every 72 hours. In this noninterventional study, the dose regimen of transdermal fentanyl (Durogesic; Janssen-Cilag GmbH, Germany) was not specified by the study protocol but was at the discretion of the treating physician. However, treatment should be carried out in accordance with the manufacturer's instructions, that is, the treatment should be initiated with the smallest dose (25 mg/h) and could be increased every 72 hours by steps of 25 mg/h, if needed.
Course of the Study
The initial study duration was 30 days. After written informed consent was obtained, demographic data and data on the rheumatologic diagnosis, the patients' medical history and data on the previous and concomitant treatment were recorded. The patients' functional capacity was assessed by the Steinbrocker method, 15 and the number of swollen or tender joints (maximum of 28 joints) was established.
After being familiarized patients rated their average pain of the last 24 hours using a 0 (no pain) to 10 (most severe pain) NRS. Using the same scale, patients individually defined a pain level that they considered long-term tolerable (treatment goal). Sleep, pain-related impairment of daily activities, and treatment satisfaction were rated using a 5-point verbal rating scale (VRS) (1 = very good or no impairment, 5 = very poor/severe). Pain intensity, sleep, pain-related impairment of daily activities, and treatment satisfaction were recorded at baseline and after 6 (optional), 15 and 30 days or, in case of premature termination, at the end of the treatment.
The Marburg questionnaire 16 was administered at the beginning and at the end of the study. It contains 7 positive statements that are each rated by the patient on a 6-point verbal assessment scale (1 = does not apply at all, 6 = applies fully). The questionnaire assesses general wellbeing, higher values correspond with better well-being.
To investigate if the short-term improvements of a treatment with transdermal fentanyl could be maintained during a long-term treatment, patients were contacted for follow-up at 6 months and at 12 months. Any adverse events that occurred were recorded throughout the observation period.
Data Analysis
Data were first checked for plausibility and completeness and then double entered into a database. For all outcome parameters, the change from baseline was tested exploratively using the Wilcoxon test for dependent samples. Missing data were imputed using the lastobservation-carried-forward method (LOCF). Adverse events were coded in accordance with the WHO Adverse Reaction Terminology.
Data were analyzed using the SAS statistical software package. P values <0.05 were generally considered significant. Results are presented as the arithmetic mean and 95% confidence interval (in brackets), unless otherwise stated.
RESULTS
Data of 226 patients (171 women, 55 men) were documented in this study. The mean age was 66 years (range 25 to 93); 173 were outpatients and 53 were inpatients. Mean pain duration was 64.7 months. The majority of patients reported pain at the knee (73%), the hands (69%), and the shoulder region (61%). Demographic data of the 226 patients are shown in Table 1 . More than half of the patients (58%) had a Steinbrocker stage index of III, 27% stage II, 11% stage IV, and 4% stage I. On average, patients displayed 7 swollen and 11 tender joints, respectively. In 168 patients (74.3%), the rheumatoid factor was positive.
In nearly all the patients, the RA was treated both with medication and nonpharmacologically. As expected, NSAIDs, glucocorticoids, and physical therapy were the main treatments (Table 2) . Disease modifying antirheumatic drugs were used by 46% of the patients. This fraction may appear low, but is explained by the fact that many of the patients were already in a late stage of the disease and showed no more active inflammation.
In 38 patients, the current pain treatment regimen included opioids. Twenty-six patients were treated with tramadol, 10 patients with morphine, 1 patient with oxycodone, and 1 patient with buprenorphine, respectively. Prior opioid treatments were terminated before initiation of a treatment with transdermal fentanyl. Conversion to transdermal fentanyl was at the discretion of the treating physician. Transdermal fentanyl was started at 25 mg/h in 192 patients (85%), 33 patients (14.5%) were started at an initial dose of 50 mg/h, and 1 patient was started at 75 mg/h. The resulting mean fentanyl dose at study start before further titration was 28.9 mg/h (27.7 to 30.1 mg/h). Forty-six of the 226 patients (20%) discontinued the treatment with transdermal fentanyl prematurely. Forty-two of these (91%) had been started with 25 mg/h and 4 (9%) with 50 mg/h. Twenty-one patients (19 started with 25 mg/h and 2 started with 50 mg/h) terminated prematurely because of adverse events, with nausea and vertigo being the most frequent adverse events. Four patients terminated prematurely because of lack of efficacy. They had been started at 25 mg/h and dropped out after the dose was increased once to 50 mg/h. For 3 of these 4, lack of compliance was given as a second reason for early termination. Another 4 patients (2 started with 25 mg/h and 2 started with 50 mg/h) were terminated because of lack of compliance. In 17 patients, treatment with transdermal fentanyl was terminated because the analgesic effect at 25 mg/h was already considered too strong (although no adverse events were reported). These patients were mostly converted to WHO-II opioids.
One hundred and eighty patients finished the study according to protocol. Of these, 95 (53%) remained at their starting dose (83 at 25 mg/h, 11 at 50 mg/h, and 1 at 75 mg/h) and 85 (47%) needed a dose increase. Of the latter, in 56 patients (66%) the fentanyl dose was increased by 25 mg/h and in 24 patients (28%) by 50 mg/ h, respectively. In only 5 patients, the dose was increased by more than 50 mg/h (3 patients by 75 mg/h, 1 patient by 100 mg/h, and 1 patient by 125 mg/h, respectively). At the end of the initial study, the average fentanyl dose (LOCF) had increased to 44.1 mg/h (40.1 to 47.2 mg/h).
Pain
The mean pain intensity at the beginning of the study was rated as 8.0 (7.82 to 8.18). During the 30-day study period, mean pain intensity decreased significantly by 4.0 (3.72 to 4.28) to 4.0 (3.75 to 4.25) (Fig. 1) .
The treatment goal, which was defined by each patient as the individual long-term tolerable pain level, ranged from 1 to 7 on the 0 to 10 NRS with a mean of 3.3 (3.16 to 3.44). In 75% of the study participants, the pain intensity dropped to or below their individually defined treatment goal after starting transdermal fentanyl. Only 7% of the patients stayed at the same pain level or got worse.
Quality of Sleep
The mean quality of nighttime sleep improved significantly from 4.0 (3.9 to 4.1) (poor) at the beginning of the study to 2.5 (2.4 to 2.6) (good to satisfactory) at the end of the observation period. Correspondingly, the disturbance of sleep due to pain decreased significantly from 3.9 (3.78 to 4.02) (severe) to 2.4 (2.3 to 2.5) (slight to moderate). The majority of patients (83.6%) reported improvement in either quality of nighttime sleep or in disturbance of sleep due to pain.
Impairment of Activities
Activities of daily living (ADL) and social activities improved significantly during the study from 4.3 (4.21 to 4.39) (severe to very severe) to 2.7 (2.58 to 2.82) (slight to moderate) and from 4.0 (3.9 to 4.1) (severe) to 2.5 (2.38 to 2.62) (slight to moderate), respectively. An improvement by at least one category on the 5-point VRS was seen in 85.4% (ADL) and 83.2% (social activities) of patients, respectively.
Treatment Satisfaction
Patients rated satisfaction with their previous pain treatment on average as 4.0 (3.9 to 4.1), which corresponds to ''poor.'' At the end of the study, patients rated the treatment including transdermal fentanyl as 2.2 (2.08 to 2.32), which corresponds to ''good.'' This was a significant improvement. In 85.4% of the patients, treatment satisfaction improved by at least one unit on the 5-point VRS. 
Marburg Questionnaire on General Well-being
The results for the individual items both at the beginning and at the end of the study are shown in Table 3 . For each item, there was a significant improvement of approximately 1.5 units, respectively.
Long-term Results
Fifty-eight patients (11 men, 47 women, mean age 66 y) could be contacted for follow-up, of which 67% had a Steinbrocker stage index of III, 25% stage II, 5% stage IV, and 3% stage I. The average number of swollen or tender joints was 7 ± 6 and 10 ± 8, respectively. The mean pain intensity of this subgroup at the end of the initial study was 3.53 (3.35 to 3.71); it remained stable at 6 months and at 12 months at 3.4 (3.23 to 3.57) and 2.92 (2.78 to 3.06), respectively. Likewise, the improvement in ADL and social activities did not deteriorate (day 30, 2.53 and 2.4; 6 mo, 2.64 and 2.47; 12 mo, 2.35 and 2.13). Consistently, treatment satisfaction remained high throughout the follow-up (day 30, 1.86; 6 mo, 1.98; 12 mo, 1.79). The mean dose of transdermal fentanyl in this subgroup increased from 28.8 mg/h at day 30 to 49.1 mg/h at 12 months.
Tolerability
During the course of the study, a total of 75 adverse events were recorded in 39 of the 226 patients (17%), most of which were considered to be related to the study medication. It should be noted that related symptoms (eg, nausea, vomiting, and loss of appetite) were counted as separate adverse events. In the majority of cases (85%), the symptoms had disappeared by the end of the study. In 40% of adverse events, a symptomatic treatment was required. Nine percent of the symptoms persisted, and no information was available in the remaining 6% of the cases. Nausea was the most frequently reported adverse event (Table 4 ). In 23 patients (10%), adverse events alone or in combination with other reasons led to a discontinuation of treatment with transdermal fentanyl. Blood pressure and heart rate did not show any clinically relevant changes during the study.
DISCUSSION
The results of this prospective, open-label, observational study show that the addition of transdermal fentanyl to a treatment regimen in patients with RA effectively improves pain, function, sleep, and well-being. It yields high treatment satisfaction and is also well tolerated over a period of 30 days.
The efficacy of transdermal fentanyl for the management of chronic noncancer pain has been demonstrated consistently in a number of studies [17] [18] [19] and has been implemented in guidelines. 20 However, only a few studies report results of the use of opioids in the treatment of RA, 9, 10 with inconsistent results. Vlak 9 reported no significant reduction in pain in 14 patients with RA treated with tramadol 200 mg daily. Moran 10 showed a significant analgesic efficacy of morphine in the treatment of patients with severe RA, but pain relief was achieved without functional improvement. Although pain relief is the expected end point of opioid therapy, pain relief without other benefits is a questionable outcome of chronic pain treatment. The results of our study demonstrate that patients with RA not only had significantly less pain (pain intensity decreased by approximately 50%), but also showed better function in daily and social activities when transdermal fentanyl was added to their treatment. Combined with improved sleep quality and less sleep disturbance, these results yielded significantly improved well-being and high treatment satisfaction in our patients.
Thirty-nine patients (17.3%) experienced adverse events, and 10% discontinued the treatment with transdermal fentanyl due to adverse events. The most frequent adverse events were nausea and vomiting. Only 3 patients (1.3%) reported constipation. These results are consistent with what has been reported in the literature (for a review see Ref. 21) . In general, transdermal fentanyl has a similar adverse event profile like other strong opioids with the advantage of causing less constipation. 21 Our results are consistent with the findings of another published study showing that transdermal fentanyl significantly improved pain control and quality of life in patients with OA and RA. 22 Like that study, our initial study covered a period of 30 days, which is short compared with a lifetime disease like RA. However, the long-term results of our study support the notion that the initial treatment effects of transdermal fentanyl in a RA population remain stable for at least 12 months at a moderate dose increase.
There are certain limitations to this study. An openlabel, noninterventional study design was chosen to gather a study-population that would be less controlled than in controlled, randomized trials. Likewise, not controlling for dose regimen and concomitant medication is more likely to reflect everyday clinical routine, although a bias is introduced to the outcome. However, the purpose of this study was not to show the efficacy of transdermal fentanyl but the safety and effectiveness of its use in patients with RA in daily routine. The use of the LOCF method may yield less conservative results.
In summary, the addition of transdermal fentanyl to a treatment in patients with RA seemed to be efficient in combination with a well-known safety and tolerability profile. Patients reported less from pain and demonstrated better function, sleep, and well-being, which resulted in an overall high treatment satisfaction. In a subgroup, these benefits remained stable over a time period of 12 months. Therefore, transdermal fentanyl is a valuable treatment option for patients with chronic pain due to RA.
